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Vascular endothelial growth factor (VEGF) inhibits differentiation and maturation of dendritic cells (DC), suggesting a potential
immunosuppressive role for this proangiogenic factor. Bevacizumab, sorafenib and sunitinib target VEGF-mediated angiogenesis and
are active against several types of cancer, but their effects on the immune system are poorly understood. In this study, VEGF and
supernatants of renal carcinoma cell lines cultured under hypoxia were found to alter the differentiation of human monocytes to DC.
Resulting DC showed impaired activity, as assessed by the alloreactive mixed T-lymphocyte reaction. Bevacizumab and sorafenib, but
not sunitinib, reversed the inhibitory effects of VEGF, but not of those mediated by tumour supernatants. Dendritic cells matured
under the influence of VEGF expressed less human leukocyte antigen-DR (HLA-DR) and CD86, and this effect was restored by
bevacizumab and sorafenib. Finally, tumour-cell supernatants decreased interleukin-12 (IL-12) production by mature DC, and such
inhibition was not restored by any of the tested drugs, delivered either as single agents or in combination. The deleterious effects of
tumour-cell supernatants were mainly mediated by thermostable molecules distinct from VEGF. These results indicate that inhibition
of the differentiation of monocytes to DC is a multifactorial effect, and that they support the development of combinations of
angiogenesis inhibitors with immunological modulators.
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Angiogenesis is a critical step in the development of solid tumours
and their metastasis, and its blockade has become a major target of
cancer therapy (Kerbel and Folkman, 2002). Renal cell carcinoma
(RCC) was the first human tumour in which inhibition of
angiogenesis, mediated by bevacizumab, a monoclonal antibody
(mAb)-neutralising vascular endothelial growth factor (VEGF),
showed clinical benefit (Yang et al, 2003a). Subsequently, RCC has
remained a platform for the development of antiangiogenic
compounds. Sunitinib, a tyrosine kinase inhibitor of VEFG
receptor (VEGFR), c-kit and platelet-derived growth factor
receptor, was superior to interferon-a (IFN-a) in a randomised
phase III trial as first line treatment of RCC (Motzer et al, 2007),
and sorafenib, another tyrosine kinase inhibitor that targets
Ras-activated factor (RAF) and VEFGR, also showed clinical
benefit in a phase III trial in which it was compared with placebo
as second-line treatment of this disease (Escudier et al, 2007a).
Bevacizumab, in combination with IFN, was also superior to single
agent IFN in another phase III trial (Escudier et al, 2007b).
Even though the main mechanism of the action of drugs that
inhibit VEGF-related pathways is antiangiogenesis, an effect of
VEGF inhibitors on the immune system has been reported. In an
earlier study, Gabrilovich et al (1996) obtained dendritic cells (DC)
from umbilical cords and described an inhibition of their ability to
induce T-lymphocyte proliferation, assessed by the mixed
lymphocyte reaction (MLR), when they were matured in super-
natant cell cultures containing VEGF. This effect was partially
reverted by anti-VEGF antibodies, showing that VEGF was
probably the cause of inhibition of DC-induced proliferation.
The same authors showed that VEGF inhibited the development of
DC and increased B lymphocytes and immature myeloid cells in
animal models (Gabrilovich et al, 1998). The proposed mechanism
of action was the interference with the activation of nuclear factor-
kB transcription factors (Ohm et al, 1999). Using the same model,
this group also showed that the addition of anti-VEGF antibodies
increased the number and activity of DC in mice implanted with
subcutaneous tumours (D459 and MethA sarcoma), although
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swithout any therapeutic effect on tumour growth (Gabrilovich
et al, 1999). Nevertheless, a combined treatment with anti-VEGF
antibodies and DC pulsed, with p53 peptides that contained
specific mutations of the implanted tumours, produced a sustained
antitumour effect, indicating potential synergism between anti-
angiogenic drugs and DC-based immunotherapy treatments for
cancer (Gabrilovich et al, 1999). Other groups have suggested that
angiogenic factors at the tumour microenvironment differentiate
DC that display features of vascular cells and are immuno-
suppressive (Conejo-Garcia et al, 2004). In addition, VEGF has
been described to mediate immunosuppression (Ohm et al, 2003),
which depends on the inhibition of differentiation and migration
of thymic lymphocyte progenitors from the bone marrow
and subsequent reduction of the numbers of CD4
þ and CD8
þ
thymocytes, which can be reverted when exposure to VEGF ceases.
Cancer therapeutic vaccines formulated with DC artificially
presenting tumour antigens are being extensively tested in clinical
trials in several tumour types (Vulink et al, 2008), including RCC
(Dannull et al, 2005). The possibility to overcoming potential
interactions of VEGF on the immune system through clinically
available angiogenesis inhibitors led us to evaluate the influence of
such drugs on DC differentiation from monocytes. A recent report
has documented the inhibitory effects of sorafenib, but not of
sunitinib, on DC maturation (Hipp et al, 2008). Maturation is the
gene expression programme that renders DC capable of mediating
T-cell expansion and activation (Steinman, 2008). Maturation is
triggered by microbial biomolecules (such as, lipopolysaccharide
(LPS) or bacterial DNA), proinflammatory cytokines and ongoing
T-cell responses. In spite of the reports on the effects of VEGF on
DC, little is known about the effects of these compounds on the
differentiation of DC from myeloid precursors. In this study, the
effects of soluble VEGF and of VEGF-containing supernatants from
RCC cells were assessed on monocytes to DC differentiation
cultures. The influence of bevacizumab, sorafenib and sunitinib on
such cultures was defined.
MATERIALS AND METHODS
DC generation and maturation
Dendritic cells were generated from filter buffy coats (FBC)-
derived monocytes donated by healthy human donors (Meyer et al,
2005). The protocol for obtention of FBC was approved by the
Ethics Committee of our institution and was carried out on donors
who gave informed consent. Isolated mononuclear cells were
subjected to positive selection using anti-CD14-conjugated para-
magnetic beads and purified using the AutoMACS system
according to the manufacturer’s instructions (Miltenyi Biotec,
Bergisch Gladbach, Germany). Purified monocytes were cultured
for 7 days in AIM-V serum-free media (Gibco-BRL, Gaithersburg,
MD, USA), supplemented with granulocyte-macrophage colony-
stimulating factor (GM-CSF) (1000Uml
 1; Leukine, Berlex,
Richmond, CA, USA) and interleukin-4 (IL-4, 500Uml
 1;R & D
Systems, Minneapolis, MN, USA). Cytokines were added every 2
days. Dendritic cells were matured with clinical-grade tumour
necrosis factor-a (TNF-a;5 0 n g m l
 1; Boehringer Ingelheim,
Ingelheim, Germany), IFN-a (1,000IUml
 1; Schering-Plough,
Kenilworth, NJ, USA) and poly I:C (20mgml
 1; Ampligen,
Bioclones, Tokai, South Africa) for 48h.
Maturation was confirmed by assessing increases in the
immunofluorescence of CD80, CD83, CD86 and human leukocyte
antigen-DR (HLA-DR), as well as variations in CD1a. Flow
cytometric analysis for immature and mature DC was performed
at days 7 and 9, using a FACSCalibur Flow Cytometer (Becton
Dickinson, San Diego, CA, USA). Purified anti-VEGFR-1 and
VEGFR-2 mAbs were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and purified anti-VEGFR-3 mAbs from
R&D Systems. Indirect immunofluorescence was performed with
anti-mouse IgG1-FITC (Dako, Glostrup, Denmark). Cell viability
was confirmed by the trypan blue exclusion test. Recombinant
human VEGF 165 (25ngml
 1, R&D Systems), bevacizumab
(rhumAb-VEGF, Avastı ´n, 1mgml
 1, Roche, Basel, Switzerland),
sorafenib (Nexavar, 10ngml
 1, Bayer, Berlin, Germany) and
sunitinib (Sutent, 10ngml
 1, Pfizer, New York, NY, USA) were
used during DC differentiation. For experiments with supernatant
of RCC line cultures, we added 1:5 (v/v) ratio of the RCC-10
supernatant to the culture medium of DC.
Cell culture and reagents
Parental von Hippel–Lindau (VHL)-negative RCC-10 cells,
originally cultured from a clear cell renal adenocarcinoma case
(Krieg et al, 2000; Cuevas et al, 2003), and a clone derived by stable
transfection of the VHL gene (VHLþ53), were kindly provided by
Dr Luis del Peso (CSIC-UAM, Madrid, Spain). The cells were
maintained in an RPMI 1640 medium with GLUTAMAX-I
(Invitrogen, Carlsbad, CA, USA). The culture medium was
supplemented with 100unitsml
 1 penicillin, 100mgml
 1 strepto-
mycin and 10% foetal bovine serum. To perform hypoxic
experiments, hypoxia was induced by exposing cell cultures to
1% oxygen for 24–48h, using a hypoxic workstation (Cuevas et al,
2003).
MLR
Dendritic cells were cultured in 96-well plates in an AIM-V
medium. A total of 2 10
5 lymphocytes from a distinct donor were
added on day 9 at different Tcell/DC ratios (80:1, 40:1 and 20:1).
After 3 days, the [methyl-
3H]thymidine uptake was determined by
the addition of 1mCi of [methyl-
3H]thymidine (25Cimmol
 1;
Amersham, Uppsala, Sweden) for 16–20h. At the end of this
labelling time, the [methyl-
3H]thymidine uptake was determined
by transferring cells to 96-well filter microplates (Unifilter-96
GF/C, PerkinElmer, Boston, MA, USA) and adding 25ml of liquid
scintillation (Microscint O, PerkinElmer) to measure radioactivity.
Technical controls were from phytohemagglutinin (PHA)-stimu-
lated human lymphocyte populations from a single individual.
Cytokine measurement
Renal cell carcinoma culture supernatants (10
6 cells/ml) were
assayed for VEGF production at 24 and 48h with an enzyme-linked
immunoabsorbent assay (ELISA) kit (R&D Systems). Interleukin-
6, IL-8, IL-10, TNF-a and IL-12 were simultaneously analysed by
microparticle-based flow cytometry (Cytometric Bead Array) in
supernatant samples of DC cultures at baseline and on day 2,
according to the manufacturer’s instructions (BD Bioscience, San
Jose, CA, USA).
Indoleamine 2,3-Dioxygenase (IDO) activity measurement
Indoleamine 2,3-Dioxygenase (IDO) activity in DC culture super-
natants was measured by high-performance liquid chromatogra-
phy (HPLC). The samples were deproteinised by mixing 100ml
supernatant and 100ml of 30% (w/v) trichloroacetic acid. After
centrifugation (4min at 10000g), 25ml of the supernatant was
added to a vial containing Na2HPO4 buffer of 125ml (HPLC:
Hewlett-Packard Series 1100; Agilent Technologies Inc., Santa
Clara, CA, USA) using a 5mM column C18 Symmetry Shield
(Waters Corporation, Milford, MA, USA). The liquid chromato-
graphy parameters were injection volume: 100ml; flow:
0.8mlmin
 1; stop time: 15min; maximum pressure: 350bar. The
mobile phase was 15mM sodium acetate (pH 4) with 27mll
 1
acetonitrile. The IDO activity is proportional to the [kynurenine]/
[tryptophan] ratio. Kynurenine concentration was measured at
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s360nm and tryptophan at 285nm, with a spectrophotometer
coupled to HPLC. A standardised curve to measure kynurenine
and tryptophan concentrations was plotted and assessed.
Arginase activity assay
Cell lysates were tested for arginase activity by measuring the
production of urea derived from L-arg. A volume of 100ml of cell
lysate was treated with Cell Lysis Buffer (Cell Signaling Techno-
logy, Danvers, MA, USA). The resulting lysate was added to 100ml
of an activation solution (Tris-HCl 25mM, pH 7.4, MnCl2 5m M).
The mixture was heated for 10min at 561C, mixed with 100mlo f
0.5 M arginine and incubated for 30min at 371C. The reaction was
interrupted with 200ml of an acid solution (H2SO4/H3PO4/H2O;
1:3:7 (v/v/v)) and the samples were boiled for 45min with 20mlo f
9% (v/v) a-isopropiophenone in absolute ethanol. The enzymatic
activity was assessed by colorimetric reaction in a spectro-
photometer at 540nm using a standard curve.
Fractions of RCC by dialysis and filtration
Renal cell carcinoma supernatant was fractionated to determine
the molecular weight of the inhibitory molecules using centrifugal
filters (Microcon, Millipore, Billerica, MA, USA) of 10, 30, 50 and
100kDa. The collected fractions were tested on monocytes
differentiating to DC by incubation with IL-4 and GM-CSF for
7 days. The only fraction that did not produce the inhibition of
full differentiation of DC from monocytes was below 10kDa. To
know the more exact the molecular weight, the RCC supernatant
was included in a 3.5kDa dialysis cassette (Slide-A-Lycer Dialysis
Cassette; 3500 MWCO; Pierce, Rockford, IL, USA) for 2h at room
temperature and overnight at 41C under continuous stirring.
Thereafter, the supernatant with moieties of molecular weight over
3.5kDa was fractionated using the same process. To assess
thermostability of the putative inhibitory factor, RCC supernatants
were boiled at 1001C for 5min.
RESULTS
RCC culture supernatants contain abundant VEGF that is
increased by hypoxia
Vascular endothelial growth factor levels were measured in the
culture supernatant from RCC-10 and VHLþ53 tumour cell lines
under normal and hypoxic (1% O2) conditions (Figure 1A). Renal
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Figure 1 Tissue culture supernatants from RCC cells contain VEGF and suppress differentiation of MLR-stimulating DC from monocytes. (A) Vascular
endothelial growth factor concentrations measured by ELISA in the 24 and 48h conditioned media from B80% confluent cultures of the indicated cell lines.
Renal cell carcinoma-10 is a renal cell carcinoma with VHL deficiency. VHLþ53 is a stable transfectant recovering the VHL expression. Cultures were
carried out in normoxia (21% O2) or hypoxia chambers (1% O2) as indicated. HT-29 human colon carcinoma cell supernatants were used as control
supernatant. (B) Lymphocyte proliferation at the indicated DC to allogenic PBL ratios, as induced by DC differentiated for 7 days from monocytes in the
presence of GM-CSF and IL-4 with or without 1:5 (v/v) of the indicated conditioned media. After differentiation, DC were matured for 48h with TNF-a,
IFN-a and poly I:C. Conditioned media were removed when indicated by three washes. Anti-VEGF mAb (bevacizumab) was added at the indicated
concentrations for the duration of the differentiation culture. Mature DC differentiated without additives were used as positive control. Data represent
mean±s.d. from three experiments. ***Po0.001, statistical analyses were performed by the Kruskal–Wallis statistical test.
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scell carcinoma-10 lacks VHL expression, whereas VHLþ53 is a
transfected revertant for this gene that controls the hypoxia
response. Exposure to hypoxia for 48h stimulated VEGF secretion
in both cell lines. Vascular endothelial growth factor production
under hypoxia was higher by RCC-10 than by VHLþ53, despite
the absence of the VHL expression. The supernatant of RCC-10
under 48h hypoxia was chosen for subsequent experimentation.
Human DC differentiated in the presence of VEGF or RCC
supernatants show impaired ability to induce T-cell
proliferation, as assessed by MLR
Dendritic cells were differentiated from CD14
þ monocytes for 7
days by GM-CSF and IL-4 in the presence of either supernatants
from RCC cultured under hypoxic conditions (Figure 1B) or
from VEGF (Figure 2A), leading to a strong inhibition of their
ability to induce allogenic T-cell proliferation, as determined by
the primary MLR. This inhibition did not take place if tumour-cell
supernatants were removed at 24h, but remained if supernatants
were washed after 96h of culture (Figure 1B). The supernatants
from other cell lines in Figure 1 showed similar effects (data not
shown).
Bevacizumab and sorafenib reverse the effects induced by
VEGF on DC activity. Neither of the drugs, as single agents
or in combination, reversed the inhibitory effects of RCC
culture supernatants
The addition of bevacizumab or sorafenib restored the MLR of DC
differentiated in the presence of VEGF to baseline levels, whereas
sunitinib did not (Figure 2A). As the activity of indoleamine
2,3-dioxygenase (Munn et al, 2002) or arginase (Ochoa et al,2 0 0 7 )
can decrease the ability of DC to stimulate T cells, we tested the
activity of both enzymes in DC differentiated under the effects of
VEGF, without finding evidence of increased activity even in the
presence of pharmacological antagonists (Supplementary Figure 1).
The decrease in MLR stimulating activity caused by RCC culture
supernatants could not be restored by bevacizumab, sorafenib or
sunitinib, delivered either as single agent or in combination
(Figures 1B and 2B). Therefore, it can be concluded that VEGF is
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Figure 2 Vascular endothelial growth factor and RCC supernatants during monocyte differentiation to DC inhibit MLR-stimulating activity of resulting DC.
Vascular endothelial growth factor-mediated inhibition is reversible by bevacizumab and sorafenib. (A) CD14þ monocyte cultures as in Figure 1 were set
up in the presence of VEGF and the indicated VEGF inhibitors. In all the experiments, TNF-a, IFN-a and poly I:C were added to induce DC maturation for
48h, including the control culture. (B) Anti-VEGF agents in different combinations are tested at the indicated concentrations to reverse the inhibition in the
MLR from mature DC that had been differentiated in the presence of RCC supernatants. Mature DC without VEGF or RCC supernatants were used as
positive controls. Microcultures of allogenic PBL without DC are plotted as negative controls. Results in panels a and b represent the mean±s.d. from four
different experiments.
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snot the only or main mediator of the deleterious effect played by
RCC supernatants on DC differentiation from monocytes.
VEGF and RCC supernatants induce changes in the surface
phenotype of DC
We determined the phenotype of DC differentiated with and
without recombinant VEGF or RCC supernatants. Dendritic cells
were maturated with a cocktail containing TNF-a, IFN-a and poly
I:C (all manufactured under good manufacturing practice condi-
tions). We assessed the surface expression of CD1a, CD11c, CD80,
CD83, CD86, HLA-DR and CD14 using flow cytometry analyses
(Figures 3A and B). The most relevant effects induced by VEGF on
mature DC were marked decreases in the intensity of CD11c, CD86
and HLA-DR. These effects were completely reversed by the
addition of bevacizumab and sorafenib. Sunitinib also restored the
normal expression of CD11c, but not of CD86 and HLA-DR.
Supernatants from RCC decreased the expression intensity of
CD11c, CD83, CD86 and HLA-DR to some extent . In these cases,
bevacizumab and sorafenib restored CD86 and HLA-DR but not
CD83. Renal cell carcinoma supernatants, but not VEGF, led to DC
cultures in which cells were more adherent and presented spread
morphology, which was more reminiscent of macrophages under
phase contrast-microscopy (Supplementary Figure 2).
It is of note that DC differentiated with VEGF did not repress the
MLR stimulating activity when added to third-party DC/T cell
cultures, thus revealing the fact that VEGF yields less-active DC
rather than suppressive DC (Supplementary Figure 3).
Addition of VEGF or RCC supernatants during DC
maturation did not alter the MLR-promoting activity of DC
In contrast to monocyte to DC differentiation cultures, neither
VEGF nor RCC supernatants altered the MLR-stimulating activity
of DC if they were added to the culture during the 48h of
maturation as induced by the combined effects of TNF-a, IFN-a
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Figure 3 Vascular endothelial growth factor and RCC supernatants added to DC differentiation cultures inhibit maturation-induced surface markers on
DC: effects of bevacizumab, sorafenib and sunitinib. Dendritic cells obtained from monocytes in 7-day cultures with GM-CSF and IL-4 were analysed by
surface immunostaining and flow cytometry for the indicated leukocyte differentiation antigens before and after maturation in the presence of TNF-a, IFN-a
and poly I:C. As indicated, recombinant VEGF (A) or RCC supernatants (B) were added during differentiation. When indicated, bevacizumab, sorafenib or
sunitinib was also added during the differentiation cultures. Values are expressed as mean±s.e.m. of four different experiments. **Po0.01,***Po0.001,
statistical analyses were performed by the Kruskal–Wallis statistical test. In all cultures set up with CD14
þ cells, the expression of CD14 was lost, so at the
end of the cultures o1% cells were CD14
þ.
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sand poly I:C (Figure 4). This indicates that once differentiated, DC
are less sensitive to the effects of VEGF or RCC supernatants with
regard to activation/maturation, at least when triggered by these
powerful maturation-inducing agents.
RCC culture supernatants, but not VEGF, decrease the
production of IL-12 by mature DC
We determined concentrations of IL-12, IL-10, IL-6 and IL-8 in
cultures of immature and mature DC, using microparticle-based
flow cytometry assays. It is interesting that the presence or absence
of VEGF during differentiation did not change the production of
IL-6, IL-8, IL-10 and IL-12. It is surprising that the addition of
sunitinib during DC differentiation dramatically reduced IL-12
and, to a lesser extent, IL-10 concentrations (Figure 5A and
Supplementary Figure 4, showing dose dependency). Such effects
did not occur when DC differentiation cultures were exposed to
either bevacizumab or sorafenib, suggesting a mechanism of action
that is dependent not on VEGF-R but rather on an alternative
pathway (Figure 5A).
We also measured the same cytokines on DC from cultures
either conditioned or not with (1:5 (v/v)) hypoxic renal carcinoma
cell-culture supernatant. The supernatant from the cell lines
inhibited IL-12 production almost completely, and such inhibition
was maintained in spite of the addition of antiangiogenic drugs.
The supernatant did not alter the levels of the other assessed
cytokines (Figure 5B), further indicating the functional viability of
the cultures and suggesting immunomodulatory effects.
The effects of RCC culture supernatants on DC activity are
mainly mediated by small thermostable molecule/s and
cannot be reversed by VEGF pharmacological antagonism
As we could not revert the inhibition of MLR activity caused by
RCC culture supernatants with either of the antiangiogenic
compounds, we fractionated the RCC-10 supernatant to determine
the molecules that could cause this effect.
Filtration fractions showed that small molecule/s of o10kDa
suppressed the MLR activity of DC (Figure 6). Further fractionation
by dialysis pre-excluding molecules o3.5kDa showed that the
activity was partially recovered when molecules 43.5kDa were
excluded. Accordingly, most of the inhibitory activity can be traced
to the 3.5–10kDa range. Moreover, such inhibitory activity persisted
after heating the supernatant for 5min at 1001C (Figure 6).
These results conclude that small soluble molecules distinct
from VEGF (described as a moiety in the 35–45kDa range) are the
main mediators of decreased T-cell-stimulating activity in DC
differentiated from monocytes in the presence of RCC culture
supernatants.
DISCUSSION
The treatment of metastatic kidney cancer has rapidly evolved
during the last few years, and a large number of targeted molecules
have either already shown efficacy in phase III trials or are
in advanced stage of clinical development, replacing former
immunotherapeutic approaches (Schrader and Hofmann, 2008).
Nevertheless, immunotherapy may retain a role in the treatment of
this disease. It must be remembered that the only treatment that
can induce cure in some patients with metastatic renal cell
cancer is high-dose intravenous IL-2 (Yang et al, 2003b;
McDermott et al, 2005). Moreover, immunotherapy with vaccines
is the only treatment that has shown clinical efficacy as an adjuvant
treatment of resected RCC (Jocham et al, 2004). Finally, a large
number of treatments based on the modulation of immunotherapy
are being developed (Melero et al, 2007) and some of them
are being tested in patients with metastatic RCC, suggesting
that, in the near future, combinations of targeted agents with
new immunotherapeutic approaches might become a reality
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s(Coppin et al, 2008). In addition, as mentioned earlier, VEGF
interferes with the development and function of DC (Gabrilovich
et al, 1996, 1998), and such an effect can be blocked by anti-VEGF
antibodies. Therefore, the study of potential interactions between
targeted agents currently used in the treatment of RCC and the
immune system is of interest.
Our data confirm that VEGF inhibits the functional differentia-
tion of DC, and impairs their ability to induce allogenic T-cell
proliferation as shown by the decrease in the allogenic MLR
assay. Such an inhibition was not dependent on indoleamine
2,3-dioxygenase or on arginase activity factors, which have been
described as immunosuppressive in DC and other myeloid cells
(Munn et al, 2002; Ochoa et al, 2007). The addition of either
sorafenib or bevacizumab reverted the effects of VEGF on DC.
Sunitinib did not restore the ability of DC to induce a normal MLR,
despite the fact that the concentrations used were in the range as
those observed in cancer patients (31.8–65.9ngml
 1) (Faivre et al,
2006). The immune phenomena of these kinds in RCC patients
might be crucial.
To mimic in vivo conditions, we assessed the effects of
differentiating DC in the presence of VEGF-containing super-
natants from RCC cell lines cultured under hypoxic conditions.
The supernatants induced a strong inhibition of DC differentiated
in such a manner that it was not reverted by the addition of any of
the anti-VEGF tested drugs. Moreover, combinations of the drugs
did not have any restoring effects on the MLR decrease induced by
the supernatants. Fractionation of those supernatants showed that
small molecule/s 43.5kDa and o10kDa suppressed the MLR
activity of DC, and that such molecules were thermostable. For this
reason, metabolic products, such as tryptophan metabolites, can
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salso be excluded as being responsible for the suppression. These
results indicate that tumour cells exert their inhibitory function on
differentiating DC through soluble factors distinct from VEGF,
although VEGF could also be involved to a lesser extent.
Changes in DC differentiated in the presence of recombinant
VEGF or RCC supernatants included marked decreases in CD11c,
CD86 and HLA-DR expressions, which were completely reverted
by bevacizumab and sorafenib, whereas sunitinib only restored
normal expression of CD11c. The events in the transition
from monocyte to DC are important not only because they
represent a popular method of generating DC for immunotherapy
(Vulink et al, 2008) but also because they might resemble the
physiological differentiation of DC from myeloid precursors. The
effect of VEGF on monocytes is not surprising because these
leukocytes express abundant levels of the three identified receptors
for this cytokine (Supplementary Figure 5). Moreover, during
differentiation culture to DC, VEGFRs are downregulated.
It is interesting that, neither VEGF nor RCC supernatants were
able to inhibit MLR if they had been added only during DC
maturation/activation, rather than during the 7-day differentiation
culture from monocytes. This indicates that mature DC might be
more resistant to the effects of RCC supernatants or VEGF.
Alternatively, the good manufacturing practice-compliant matura-
tion cocktail that we use may be of such a strength that is not
amenable to inhibition by these agents.
Exposure to VEGF during differentiation did not alter the
secretion of several cytokines, including that of IL-12, IL-10, IL-6
and IL-8. The addition of sunitinib during DC differentiation
induced a marked decrease in IL-12 concentrations and a less
relevant reduction in IL-10 secretion. Bevacizumab and sorafenib
did not reproduce these effects. These results suggest that the IL-12
inhibition induced by sunitinib is not mediated by the VEGF
pathway, and may have relevant implications when exploring
combinations of sunitinib with other immunotherapeutic
strategies. Indeed, sunitinib and sorafenib are far from being
specific inhibitors of a single tyrosine kinase and have been shown
to inhibit various kinases with different ICs50.T h e s ei n c l u d e d
signalling pathways known to be critical in leukocyte biology
(Karaman et al, 2008). Therefore, this type of VEGF-R-independent
effects is not unexpected to see. Renal cell carcinoma culture
supernatants also inhibited IL-12 production, and neither of the
drugs tested reversed this effect, further supporting the fact that
IL-12 inhibition is dependent not on the VEGF pathway but on
other unidentified factors. Interleukin-12 is critical for therapeutic
immunity against cancer (Mazzolini et al, 2003). Artificial enhancement
of IL-12 production by DC strengthens elicited immunity and
therapeutic potential (Melero et al, 1999; Mazzolini et al, 2005).
Therefore, selective inhibition of IL-12 is likely to be suppressive
for cellular immune responses.
Other authors have also evaluated the effects of sorafenib and
sunitinib on DC (Hipp et al, 2008). They reported that sorafenib,
but not sunitinib, inhibited DC function, assessed through the
expression of cytokines and CD1a. The inhibitory effects were
mediated by the inhibition of phosphatidylinositide 3-kinase
production and mitogen-activated protein kinases, as well as by
nuclear factor-kB signalling. They treated C57BL/6 mice with both
drugs, and found that sorafenib significantly reduced the induction
of antigen-specific T cells, whereas sunitinib reduced the number
of regulatory T cells in peripheral blood. On the basis of these
findings, they concluded that sorafenib does not seem to be a good
candidate for combination with immunotherapeutic approaches,
whereas sunitinib does. The main difference between both studies
is that whereas Hipp et al (2008) investigated the effects on already
differentiated DC, we focused on the transition from myeloid
immature precursors to DC.
Our experimental observations join the literature on potential
mechanisms accounting for immune dysfunction in RCC. Direct
proapoptotic effects of RCC cells on human T cells have been
reported as being mediated by the FasL expression and ganglio-
sides released into the surrounding media (Das et al, 2008).
Gangliosides are unlikely mediators of the effects on monocytes
because of lower molecular weights than that of the expected
factors according to Figure 6. In RCC patients, sunitinib treatment
improves type I responses by T lymphocytes with decreases in
regulatory T cells (Finke et al, 2008). Whether this is mediated
directly on T cells within the cancer-modified environment or by
indirect effects involving myeloid leukocytes, such as DC, remains
to be seen. The effects of sunitinib downmodulating the ability for
IL-12 production in our cultures are to be reconciled with the
improvements of type I responses seen in the patients and possibly
related to the complexity of the in vivo system (Finke et al, 2008).
In conclusion, our study shows that bevacizumab and sorafenib,
but not sunitinib, reverse the inhibitory effects of recombinant
VEGF on DC differentiation, but not of those mediated by RCC
culture supernatants, which are mainly mediated by other
unidentified substance(s). The changes induced by VEGF on
mature DC included a reduced expression of HLA-DR and CD86,
which was also reverted by bevacizumab and sorafenib. Finally,
RCC culture supernatants and, surprisingly, sunitinib decreased
IL-12 production by mature DC. Such inhibition was not restored
by any of the tested drugs, delivered either as single agents or in
combination. Moreover, our data indicate that soluble factors
from RCC exert effects on monocyte to DC differentiation,
which renders functionally impaired DC for T-cell stimulation.
Fortunately, such altered DC by tumour-soluble factors do not
interfere with the function of healthy DC differentiated apart from
the influence of tumour cells. Biochemical identification of the
inhibitory factors is the next step to progress in our understanding
of the new described phenomena.
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